The neuregulin family of structurally related glycoproteins comprises products from four distinct but related genes, Nrg-1, Nrg-2, Nrg-3, and Nrg-4. Through alternative splicing or the use of alternative promoters, Nrg-1 has been shown to encode more than 14 soluble or transmembrane proteins. The extracellular domain of the transmembrane NRG1 isoforms can be proteolytically cleaved to release soluble growth factors. All NRG1 isoforms contain an EGF-like domain ( alpha - or beta -splice variant that differ in their C-terminal region) that is required for their direct binding to the ErbB3 or ErbB4 receptor tyrosine kinases. The ErbB3 or ErbB4 subsequently recruits and heterodimerizes with ErbB2, resulting in tyrosine phosphorylation and NRG1 signaling. NRG1 isoforms can be classified into three major subtypes. Type I (Neu Differentiation Factor, NDF; Heregulin, HRG; Acetylcholine Receptor Inducing Activity, ARIA) and type II (Glial Growth Factor, GGF) NRG1s have an immunoglobulin (Ig)-like domain N-terminal to the EGF-like domain. Type I NRG1s differ from type II NRG1s by having a glycosylation-rich domain between the Ig-like and the EGF-like domains. Type III NRG1s (Sensory and Motor neuron-Derived Factor) lacks the Ig-like domain but has a cysteine rich domain (CRD) instead. NRG1 isoforms show distinct spatial and temporal expression patterns. These proteins play important roles during development of both the nervous system and the heart. They have been shown to regulate the selective expression of neurotransmitter receptors in neurons and at the neuromuscular junction, and promote the differentiation and development of Schwann cells from neural crest stem cells. NRG1s have also been shown to be involved in the establishment of the oligodendroglial lineage.
Post-translational: Proteolytic cleavage close to the plasma membrane on the external face leads to the release of the soluble growth factor form.N- and O-glycosylated. Extensive glycosylation precedes the proteolytic cleavage (By similarity).
生物活性
Measured in a cell proliferation assay using MCF‑7 human breast cancer cells. The ED50 for this effect is 2.1 ng/mL.
10.0 kDa, under reducing conditions; 10.9 & 16.9 & 23.9 kDa, under non-reducing conditions.
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, 5% Trehalose, 5% Mannitol, pH 7.4
浓度
见COA
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.5 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
Store at -20℃ for 12 months. Upon reconstitution, it is recommended to aliquot. Avoid freeze/thaw cycle.
图片
Recombinant Human NRG1-beta 1/HRG1-beta 1 EGF Domain Protein (rp215080) - Bioactivity Measured in a cell proliferation assay using MCF‑7 human breast cancer cells. The ED50 for this effect is 2.1 ng/mL.
Recombinant Human NRG1-beta 1/HRG1-beta 1 EGF Domain Protein (rp215080) - SDS-PAGE 3 μg/lane of Recombinant Human NRG1-beta 1/HRG1-beta 1 EGF Domain Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 10.0 kDa under reducing conditions and 10.9 & 16.9 & 23.9 kDa under non-reducing conditions. NRG1 may form multimers through glycosylation modifications (PMID: 12648463).
ZJ25F1028376
危险品化学品经营许可证（带存储）